Afya Limited (AFYA) M&A Call Transcript

Yduqs and Afya held a conference call regarding their proposed business combination, with combined-company information based on each firm's 2Q26 financial metrics. Management framed the merger around the growth prospects and future operating and financial performance of the combined entity, while cautioning that projections are subject to Brazilian macroeconomic, market and operating risks. The excerpt provides no transaction value, exchange ratio, synergy target, timetable or regulatory-status detail.

Analysis

The investable question is not strategic logic but consideration structure, exchange ratio, and governance allocation—none of which is supplied. AFYA’s premium medical-education multiple could be diluted if it issues equity at a discount to absorb YDUQ3’s broader, lower-margin education exposure; conversely, a cash-heavy offer would introduce leverage and BRL funding risk. Until pro forma enrollment mix, EBITDA synergy targets, integration costs, and ownership are disclosed, the announced combination is an event-risk situation rather than a fundamental long.

Near-term, AFYA’s ADR should trade on implied deal value and probability of completion, with the largest discount likely driven by Brazilian antitrust review, shareholder approvals, and FX rather than operating performance. The key 1-3 month catalyst is a definitive filing that quantifies revenue synergies versus campus rationalization costs and defines who controls the combined board; aggressive synergy assumptions without a timetable would warrant multiple compression. Over 6-18 months, the structural upside is pricing power and lower customer-acquisition expense in medical education, but that is offset by regulatory risk if consolidation increases scrutiny of tuition, accreditation capacity, or student-financing exposure.

Consensus may overvalue scale while underweighting adverse selection: AFYA shareholders are effectively exchanging a focused, scarce-seat asset for exposure to a more cyclical Brazilian higher-education demand base. A favorable exchange ratio can still be value-destructive if the combined entity’s return on invested capital falls below AFYA’s standalone reinvestment return. The thesis is falsified positively by disclosed, credible cost/revenue synergies sufficient to preserve AFYA-level margins and negatively by a material equity issuance, a CADE remedy requiring asset divestitures, or pro forma net leverage above management’s stated deleveraging capacity.

Key Decisions for Investors

• Do not initiate a directional AFYA position before definitive merger terms. Set an event alert for the exchange ratio, cash/equity mix, pro forma leverage, board composition, and CADE filing; these inputs are required to calculate a deal spread and standalone downside.
• For holders, retain only a reduced event-risk position through the next formal transaction disclosure and hedge Brazil/BRL beta with a partial EWZ hedge if AFYA’s ADR begins pricing a premium unsupported by disclosed synergies. Reassess if the implied premium exceeds the value of quantified cost savings after integration costs.
• If AFYA trades at a material discount to disclosed all-stock consideration after terms are released, evaluate a merger-arbitrage pair: long AFYA ADR / short the appropriate YDUQ3-equivalent exposure, sized to the final exchange ratio. Require a spread wide enough to compensate for approval, FX conversion, and liquidity risk; avoid pre-hedging before ratio disclosure.
• Avoid treating C, GS, JPM, or MS as beneficiaries: advisory participation is unlikely to be financially material relative to their earnings. The relevant read-through is instead to Brazilian education peers and regulatory-sensitive consumer credit exposures if financing terms reveal stress.